BMJ open · 2024
Electronic health record data analysis on the impact of rescue-triggered inhaled corticosteroids on controller therapy in Black and Latinx individuals from a pragmatic, open-label, patient-level randomised trial.
СтатьяРандомизированное исследованиеPragmatic Clinical TrialНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Callen Elisabeth, Israel Elliot, Cardet Juan Carlos, Fuhlbrigge Anne L, Manning Brian, Gaona Gabriela, Staton Elizabeth, Pace Wilson D
Аннотация
OBJECTIVE: The Person Empowered Asthma Relief (PREPARE) study found that as-needed inhaled corticosteroid (ICS) supplementation combined with participants' usual controller and rescue therapy reduced asthma exacerbations for Black and Hispanic/Latinx individuals. We aimed to determine whether treatment assignment to the intervention group (Patient Activated Reliever-Triggered ICS (PARTICS)) versus the control group (usual care) influenced controller therapy based on clinicians' written prescriptions.
DESIGN: Secondary data analysis of electronic health record data of a pragmatic, open-label, patient-level randomised trial.
SETTING: Practices treating asthma.
PARTICIPANTS: PREPARE study participants- Black and Hispanic/Latinx individuals with asthma.
INTERVENTIONS: Effects of adding ICS to rescue therapy among black and Hispanic adults with moderate-to-severe asthma.
OUTCOME MEASURES: For PARTICS therapy impact on patients, each month is the 28-month period (12 months prior to enrolment, the month of enrolment and 15 months after enrolment), a patient was assigned to a controller step based on a six-step classification scheme. A linear mixed effect spline model was completed for before and after enrolment data to determine controller changes over a 28-month period between the two study arms.
RESULTS: This analysis included 713 participants. Of these, 49.1% were usual care patients and 50.9% were PARTICS patients. Throughout the study, the majority of patients changed asthma controller medications in both arms. By the end of the study, the usual care patients were at a significantly higher asthma controller medication step (0.20 step higher) than the PARTICS patients.
CONCLUSIONS: Clinicians' prescribing patterns showed significant changes over time. Compared with usual care patients, PARTICS patients were on lower doses of asthma controller medications by the end of the study.
TRIAL REGISTRATION NUMBER: NCT02995733.
DESIGN: Secondary data analysis of electronic health record data of a pragmatic, open-label, patient-level randomised trial.
SETTING: Practices treating asthma.
PARTICIPANTS: PREPARE study participants- Black and Hispanic/Latinx individuals with asthma.
INTERVENTIONS: Effects of adding ICS to rescue therapy among black and Hispanic adults with moderate-to-severe asthma.
OUTCOME MEASURES: For PARTICS therapy impact on patients, each month is the 28-month period (12 months prior to enrolment, the month of enrolment and 15 months after enrolment), a patient was assigned to a controller step based on a six-step classification scheme. A linear mixed effect spline model was completed for before and after enrolment data to determine controller changes over a 28-month period between the two study arms.
RESULTS: This analysis included 713 participants. Of these, 49.1% were usual care patients and 50.9% were PARTICS patients. Throughout the study, the majority of patients changed asthma controller medications in both arms. By the end of the study, the usual care patients were at a significantly higher asthma controller medication step (0.20 step higher) than the PARTICS patients.
CONCLUSIONS: Clinicians' prescribing patterns showed significant changes over time. Compared with usual care patients, PARTICS patients were on lower doses of asthma controller medications by the end of the study.
TRIAL REGISTRATION NUMBER: NCT02995733.